Physician profile
May T Chow
NPI 1770580870
$3,442.99
in general payments reported to CMS, 2019-2025
24 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,173 · 2020: $436 · 2021: $403 · 2022: $683 · 2023: $272 · 2024: $332 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $747.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,250.14 | 2020-2025 | |
| Sun Pharmaceutical Industries INC. | $252.10 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $225.02 | 2019-2021 | |
| Amgen INC. | $202.25 | 2019-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $152.01 | 2019-2021 | |
| Galderma Laboratories, L.P. | $142.06 | 2019-2021 | |
| Fresenius USA Marketing, INC. | $135.45 | 2019-2022 | |
| Bard Peripheral Vascular, INC. | $135.33 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $120.52 | 2022 | |
| Solta Medical, A Division of Bausch Health US, LLC | $108.53 | 2019 | |
| Alexion Pharmaceuticals, INC. | $103.77 | 2019 | |
| Shire North American Group INC | $101.84 | 2019 | |
| Leo Pharma INC. | $93.88 | 2022 | |
| Mallinckrodt Enterprises LLC | $89.99 | 2019 | |
| Vifor Pharma, INC. | $87.96 | 2020-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $54.94 | 2020-2022 | |
| Akebia Therapeutics INC | $44.77 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $38.33 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.52 | 2024 | Cyltezo |
| Biocon Biologics INC | $18.94 | 2025 | Hulio |
| Arcutis Biotherapeutics, INC. | $18.67 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $15.99 | 2020 | |
| Daiichi Sankyo INC. | $13.36 | 2019 | |
| Strongbridge US INC. | $11.62 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw May Chow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.